Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1650 in Incurable Platinum Refractory Germ Cell Tumors
NCT03760081Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of imab027 in germ cell tumor (GCT) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Recommended Phase 2 Dose at 28 days and Objective Response Rate (Modified RECIST v1.1) at 26.57 weeks. Started Mar 2019; status: completed.
02
Drugs
imab027
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on NCT03760081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760081.